{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/malaria-prophylaxis/","result":{"data":{"firstChapter":{"id":"ce4f76aa-9527-5f8c-9846-98b8c95af6e4","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 7c5fa8e3-89da-4fb3-9595-8914e0a6acde --><h1>Malaria prophylaxis: Summary</h1><!-- end field 7c5fa8e3-89da-4fb3-9595-8914e0a6acde -->","htmlStringContent":"<!-- begin item 3372060f-1dc7-4448-a747-16851b3c7cba --><!-- begin field 9f9f7a00-d442-4fbd-a276-ea936683da05 --><ul><li>Malaria is a life-threatening illness caused by infection of red blood cells by Plasmodium parasites. Transmission of malaria to humans occurs through the bite of infected female Anopheles mosquitoes.</li><li>Species of Plasmodium known to cause malaria in humans include:<ul><li><em>P. falciparum</em> — found worldwide in tropical and subtropical areas. It is responsible for the majority of malaria deaths.</li><li><em>P. vivax</em> — the most common malaria parasite outside sub-Saharan Africa. <em>P. vivax</em> has dormant liver stages which can cause ‘relapses’ of malaria months or years after the initial infection.</li><li><em>P. ovale</em> — found mostly in Africa (especially West Africa) and the islands of the western Pacific. <em>P. ovale</em> has dormant liver stages which can cause ‘relapses’ of malaria months or years after the initial infection.</li><li><em>P. malariae</em> — found in South America, Asia and Africa. If untreated, <em>P. malariae</em> can cause lifelong chronic infection.</li><li><em>P. knowlesi</em> — a malaria parasite of monkeys in South-East Asia which can cause severe and sometimes fatal illness in humans.</li></ul></li><li>Assessment of a person intending to travel to a malaria endemic area involves:<ul><li>Taking a thorough history to identify travel itinerary, factors that may put the person at high risk of developing severe/fatal malaria (such as pregnancy, extremes of age and immunosuppression), past medical history (including psychiatric and seizure conditions) and drug and vaccine history.</li><li>Checking the Public Health England Advisory Committee on Malaria Prevention (ACMP) guidelines to assess the risk of malaria in specific regions to be visited and identify appropriate preventative measures.</li></ul></li><li>Prevention of malaria in the traveller includes:<ul><li>Education on malaria risk factors and clinical features — both oral and written information should be provided.</li><li>Personal protective measures such as application of insect repellent (preferably DEET), protective clothing and insecticide treated bednets — the first line of defence against vector-borne diseases is effective bite prevention.</li><li>Chemoprophylaxis (if appropriate for the area to be visited) taking into account contra-indications and co-morbid conditions.</li><li>Provision of emergency standby treatment — this is not required for most travellers but should be considered if taking chemoprophylaxis and visiting remote areas not within 24 hours of medical facilities. </li></ul></li><li>Chemoprophylaxis and measures to prevent mosquito bites do not eliminate the risk of contracting malaria (although they significantly reduce it). Therefore people travelling to an area where malaria is endemic should be advised when to suspect malaria, and to seek medical attention as soon as possible.<ul><li>Malaria can progress from mild to life-threatening disease within hours (particularly in high risk groups such as children and pregnant women) — if clinical features of malaria develop while travelling or up to one year after return early diagnosis and treatment is essential.</li></ul></li><li>Malaria prevention is only one aspect of pre-travel advice — comprehensive travel health advice based on individual risk should be provided to the traveller.</li></ul><!-- end field 9f9f7a00-d442-4fbd-a276-ea936683da05 --><!-- end item 3372060f-1dc7-4448-a747-16851b3c7cba -->","topic":{"id":"1dfdf856-ced9-50bb-8739-9ac597e749da","topicId":"fcbcecf9-c37c-4236-a0f0-e6ea3ff72076","topicName":"Malaria prophylaxis","slug":"malaria-prophylaxis","aliases":[],"chapters":[{"id":"ce4f76aa-9527-5f8c-9846-98b8c95af6e4","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"6fd40a83-7b55-56f4-97de-93dd8ba2ad8f","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"665f9f2c-5318-56d6-ac14-83dd936bdf97","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"62945b37-6310-5a07-b2dc-90e23836e367","slug":"changes","fullItemName":"Changes"},{"id":"57a7f2b1-f3c6-5c7c-be23-60a85ca3e97f","slug":"update","fullItemName":"Update"}]},{"id":"4cbf6005-cbd7-5792-be78-1e08b1755887","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"24cd959e-2b4a-53d8-9a67-2cb6351480d4","slug":"goals","fullItemName":"Goals"},{"id":"8bfd8f1f-5162-55f5-98d0-024aa470eda3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6e3197bd-4c7e-50e3-8571-464b20b486e6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"68b0fb84-1d6e-5755-9c2e-89fd57721afa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0e6ae722-735b-5e79-85d2-194cb8187380","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"66ce78ae-da4a-51bf-9d51-ae896236d71d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f8048c7c-b171-5f3b-91f0-2a353065712f","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"0f3bc680-088f-5879-bf5b-9cc85a3ea0ff","slug":"definition","fullItemName":"Definition"},{"id":"b849c9ff-c93f-5656-a227-098952e12f88","slug":"causes","fullItemName":"Causes"},{"id":"caad75c1-ac57-5c45-b040-8526b6235302","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ef83916a-1184-5356-93ba-f9bac26e167a","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a763547a-e2f3-5435-b3e5-36b2b8ad0c9e","slug":"complications","fullItemName":"Complications"}]},{"id":"254e9708-01a9-5862-801a-70f9e1fb5e84","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"3379892e-94c0-5840-a578-cb5766212c69","slug":"assessment","fullItemName":"Assessment"},{"id":"4f391cab-b5f3-563e-be8a-a7235fe6467f","slug":"clinical-features","fullItemName":"Clinical features"}]},{"id":"18712f50-06cc-5638-9851-5c50e65488b5","slug":"management","fullItemName":"Management","subChapters":[{"id":"97193dc0-631b-5bea-89f3-7e605df7f3f4","slug":"malaria-prevention-in-travellers-from-the-uk","fullItemName":"Scenario: Malaria prevention in travellers from the UK"}]},{"id":"7750a127-e87f-5079-8777-0c8f13536296","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"d4c5d3cf-2088-5d0a-94a1-af0994185aa5","slug":"drug-availability-on-the-nhs","fullItemName":"Drug availability on the NHS"},{"id":"f0cf5bcc-8534-50cf-a520-0e80e777e72d","slug":"prescribing-in-children","fullItemName":"Prescribing in children"},{"id":"2f74fd56-68c0-56c8-a07c-22482e10e67e","slug":"chloroquine","fullItemName":"Chloroquine"},{"id":"a6e70a24-4baa-514f-9d3a-a7ccb0d9b45c","slug":"proguanil","fullItemName":"Proguanil"},{"id":"2ce163bd-7fa7-51bd-8554-3a6a1cafdfa1","slug":"mefloquine","fullItemName":"Mefloquine"},{"id":"4ca8c124-4f45-50ce-a3b2-9a02219d6ab9","slug":"proguanil-plus-atovaquone","fullItemName":"Proguanil plus atovaquone"},{"id":"57e80cdf-fc37-5774-979d-f58301a7b5fb","slug":"doxycycline","fullItemName":"Doxycycline"}]},{"id":"38b67274-c723-5e50-9cdd-5cc01de962cb","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"91d3306b-2734-52a0-ac13-1adf3711008a","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"bb5bc365-9c32-5684-9333-e464e129ad67","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7b7d36b2-37d8-5815-836a-898e104a533e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2d5b97c9-c3d7-51bf-beae-65128d39bd5d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d69ddbc4-81c8-5404-8a15-7bc2502831cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c2fc1581-dd5f-5317-a19f-cfb72905246e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d7b5a2b6-f6a2-529e-8337-1780d8941d2c","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"1dfdf856-ced9-50bb-8739-9ac597e749da","topicId":"fcbcecf9-c37c-4236-a0f0-e6ea3ff72076","topicName":"Malaria prophylaxis","slug":"malaria-prophylaxis","aliases":[],"topicSummary":"Prophylaxis used depends on the area to be visited, the age of the person, contraindications to specific drugs in people with co-morbidities, and patient preference.","lastRevised":"Last revised in January 2018","nextPlannedReviewBy":"2023-01-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2023-01","nextPlannedReviewByDisplay":"January 2023","specialities":[{"id":"e174a859-759f-5b1d-898e-1a4155645e13","name":"Infections and infestations","slug":"infections-infestations"},{"id":"2454765b-1b2d-53fc-b288-17b66486f41a","name":"Preventative medicine","slug":"preventative-medicine"}],"chapters":[{"id":"ce4f76aa-9527-5f8c-9846-98b8c95af6e4","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"6fd40a83-7b55-56f4-97de-93dd8ba2ad8f","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"665f9f2c-5318-56d6-ac14-83dd936bdf97","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"62945b37-6310-5a07-b2dc-90e23836e367","slug":"changes","fullItemName":"Changes"},{"id":"57a7f2b1-f3c6-5c7c-be23-60a85ca3e97f","slug":"update","fullItemName":"Update"}]},{"id":"4cbf6005-cbd7-5792-be78-1e08b1755887","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"24cd959e-2b4a-53d8-9a67-2cb6351480d4","slug":"goals","fullItemName":"Goals"},{"id":"8bfd8f1f-5162-55f5-98d0-024aa470eda3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6e3197bd-4c7e-50e3-8571-464b20b486e6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"68b0fb84-1d6e-5755-9c2e-89fd57721afa","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0e6ae722-735b-5e79-85d2-194cb8187380","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"66ce78ae-da4a-51bf-9d51-ae896236d71d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f8048c7c-b171-5f3b-91f0-2a353065712f","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"0f3bc680-088f-5879-bf5b-9cc85a3ea0ff","slug":"definition","fullItemName":"Definition"},{"id":"b849c9ff-c93f-5656-a227-098952e12f88","slug":"causes","fullItemName":"Causes"},{"id":"caad75c1-ac57-5c45-b040-8526b6235302","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ef83916a-1184-5356-93ba-f9bac26e167a","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a763547a-e2f3-5435-b3e5-36b2b8ad0c9e","slug":"complications","fullItemName":"Complications"}]},{"id":"254e9708-01a9-5862-801a-70f9e1fb5e84","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"3379892e-94c0-5840-a578-cb5766212c69","slug":"assessment","fullItemName":"Assessment"},{"id":"4f391cab-b5f3-563e-be8a-a7235fe6467f","slug":"clinical-features","fullItemName":"Clinical features"}]},{"id":"18712f50-06cc-5638-9851-5c50e65488b5","slug":"management","fullItemName":"Management","subChapters":[{"id":"97193dc0-631b-5bea-89f3-7e605df7f3f4","slug":"malaria-prevention-in-travellers-from-the-uk","fullItemName":"Scenario: Malaria prevention in travellers from the UK"}]},{"id":"7750a127-e87f-5079-8777-0c8f13536296","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"d4c5d3cf-2088-5d0a-94a1-af0994185aa5","slug":"drug-availability-on-the-nhs","fullItemName":"Drug availability on the NHS"},{"id":"f0cf5bcc-8534-50cf-a520-0e80e777e72d","slug":"prescribing-in-children","fullItemName":"Prescribing in children"},{"id":"2f74fd56-68c0-56c8-a07c-22482e10e67e","slug":"chloroquine","fullItemName":"Chloroquine"},{"id":"a6e70a24-4baa-514f-9d3a-a7ccb0d9b45c","slug":"proguanil","fullItemName":"Proguanil"},{"id":"2ce163bd-7fa7-51bd-8554-3a6a1cafdfa1","slug":"mefloquine","fullItemName":"Mefloquine"},{"id":"4ca8c124-4f45-50ce-a3b2-9a02219d6ab9","slug":"proguanil-plus-atovaquone","fullItemName":"Proguanil plus atovaquone"},{"id":"57e80cdf-fc37-5774-979d-f58301a7b5fb","slug":"doxycycline","fullItemName":"Doxycycline"}]},{"id":"38b67274-c723-5e50-9cdd-5cc01de962cb","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"91d3306b-2734-52a0-ac13-1adf3711008a","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"bb5bc365-9c32-5684-9333-e464e129ad67","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"7b7d36b2-37d8-5815-836a-898e104a533e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2d5b97c9-c3d7-51bf-beae-65128d39bd5d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d69ddbc4-81c8-5404-8a15-7bc2502831cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c2fc1581-dd5f-5317-a19f-cfb72905246e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d7b5a2b6-f6a2-529e-8337-1780d8941d2c","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"1dfdf856-ced9-50bb-8739-9ac597e749da"}},"staticQueryHashes":["3666801979"]}